June 17, 2022
1 min watch
Save
VIDEO: Blood-based immune biomarkers help identify pancreatic cancer chemoimmunotherapies
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Robert Vonderheide, MD, DPhil, discussed the results of the phase 2 randomized study of chemoimmunotherapy for patients with metastatic pancreatic cancer.
"What we found is evidence that chemotherapy and immunotherapy can work together and offer some patients some survival benefit. We are now studying who are those patients," Vonderheide, director of University of Pennsylvania's Abramson Cancer Center, said.
"We think it's important that the way we are identifying patients is not based on sequencing or even tumor biopsies, but rather measuring the immune health in patients' blood streams as they entered the study," Vonderheide continued.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Vonderheide reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.